Bellevue Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bellevue Group’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-18,000	Closed	-$1.25M	–	143
2018 Q3	$1.25M	Sell	18,000 -15,000	-45%	-$1.14M	0.08%	120
2018 Q2	$2.5M	Hold	33,000	–	–	0.21%	81
2018 Q1	$1.74M	Hold	33,000	–	–	0.17%	86
2017 Q4	$1.76M	Sell	33,000 -48,550	-60%	-$2.7M	0.18%	86
2017 Q3	$4.86M	Sell	81,550 -50,440	-38%	-$3.05M	0.51%	55
2017 Q2	$10.4M	Buy	131,990 +64,290	+95%	+$5.26M	1.23%	31
2017 Q1	$5.62M	Buy	67,700 +27,000	+66%	+$2.01M	0.75%	48
2016 Q4	$3.23M	Buy	40,700 +11,700	+40%	+$850K	0.66%	43
2016 Q3	$2.03M	Buy	+29,000	New	+$1.61M	0.37%	74

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bellevue Group's EGRX Position: Q4 2018 in Review

Bellevue Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 18,000 shares — an estimated $1.25M sold.

Bellevue Group first reported a position in EGRX in Q3 2016 and held it in 9 quarters. The position peaked at $10.4M in Q2 2017. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

Bellevue Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Bellevue Group sold 18,000 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $1.25M.
Bellevue Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 9 quarters.
Bellevue Group's Eagle Pharmaceuticals, Inc. position peaked at $10.4M in Q2 2017.
182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on Bellevue Group's 13F filing for Q4 2018, filed 12 Feb 2019.